Quarterly Result25 May 2026, 07:51 pm
Orchid Pharma: FY26 Revenue at ₹811.33 Mn
AI Summary
Orchid Pharma Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The results include a modified opinion for consolidated financial results and an unmodified opinion for standalone financial results. Revenue from operations stood at ₹811.33 Mn for the year ended March 31, 2026. The board also approved the appointment of the Internal Auditor for the Financial Year 2026-27.
Key Highlights
- Orchid Pharma's FY26 revenue from operations is ₹811.33 Mn.
- Auditors issued a modified opinion on the consolidated financial results.
- An unmodified opinion was issued for the standalone financial results.
- Internal Auditor appointed for the financial year 2026-27.
- Board approved standalone & consolidated results for quarter and year ended March 31, 2026.
Price Impact
More from ORCHIDPHAR